SEOUL, Feb. 14 (Korea Bizwire) — Sales of the biosimilar Remsima by Celltrion Inc. reached an all-time high last year in the United States, the company said Monday. Sales of the biosimilar drug to treat autoimmune diseases jumped 13 percent on-year to US$385 million in 2021, Celltrion Healthcare said, citing industry data. Remsima references Janssen [...]
SEOUL, Feb. 12 (Korea Bizwire) — Buying of COVID-19 self-test kits will be restricted to five units per purchase for three weeks, as the government works to stabilize the supply in light of the recent surge in at-home treatment patients, according to officials Saturday. According to the Ministry of Food and Drug Safety, the purchase [...]
SEOUL, Feb. 11 (Korea Bizwire) — South Korea’s leading botox maker Hugel Inc. said Friday that it will make inroads into the United States, the world’s largest botulinum toxin market, this year. Earlier, the company sought a marketing authorization of its botulinum toxin product, Letybo, with the U.S. Food and Drug Administration (FDA) for the [...]
SEOUL, Feb. 9 (Korea Bizwire) — SK Telecom Co., South Korea’s largest mobile carrier, said Tuesday that it had entered into a partnership with five national universities to develop an artificial intelligence (AI)-based veterinary image diagnosis solution for pets. The solution will be designed to ensure the diagnosis of pets in a faster and more [...]
SEOUL, Feb. 7 (Korea Bizwire) — South Korean pharmaceutical giant Celltrion Inc. said Monday that its inhaled version of an antibody treatment candidate against COVID-19 has shown to be safe in a clinical trial. A total of 24 healthy volunteers were enrolled in a phase one clinical trial conducted by Celltrion’s global partner, Inhalon Biopharma, [...]
SEOUL, Feb. 3 (Korea Bizwire) — South Korean biopharmaceutical firm Samsung Bioepis Co. said Thursday it has won approval from Canadian authorities for the sale of its biosimilar cancer drug Ontruzant. The Health Canada has approved Ontruzant — a biosimilar product referencing Switzerland-based Roche Holding’s Herceptin, also known as Trastuzumab — for treatment of adults [...]
SEOUL, Jan. 28 (Korea Bizwire) — Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, said Friday that it has reached a deal with Biogen Inc. to buy the U.S. drugmaker’s entire stake in Samsung Bioepis for US$2.3 billion. Currently, Biogen owns 50 percent minus one share in Samsung Bioepis, the joint venture [...]
SEOUL, Jan. 26 (Korea Bizwire) — A group of South Korean scientists developed a screening biosensor that can detect COVID-19 variants within 30 minutes, whose test results are as accurate as polymerase chain reaction (PCR) tests, a state-run science institute said Wednesday. The team led by Lee Kwan-hyi of the Korea Institute of Science and [...]
SEOUL, Jan. 20 (Korea Bizwire) — Three South Korean companies are among 27 drugmakers chosen to produce low-cost versions of Merck & Co.’s COVID-19 pill for low- and-middle-income countries, the Medicines Patent Pool (MPP) and Seoul’s health ministry said Thursday. The U.N.-backed public health organization announced that it signed sublicense agreements with 27 generic drug [...]
SEOUL, Jan. 14 (Korea Bizwire) — South Korean pharmaceutical giant Celltrion Inc. said Friday its COVID-19 antibody treatment has won temporary approval from Swedish authorities. Swissmedic granted Temporary Authorization of Rekirona for adult COVID-19 patients who do not require supplementary oxygen treatment and are at high risk of developing into severe cases. The approval will [...]